Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Chinese cargo containers on map of USA. Import of chenese goods concept. 3D rendered illustration.

China

The Rise of China Innovation in the Time of Trump

With incoming president Donald Trump threatening a trade war with China, experts told BioSpace that the new administration will likely understand why medicines should be treated differently.

January 16, 2025

4 min read

Annalee Armstrong

Business

A Conversation with Peter Marks: Insights into GenScript Biotech Forum 2025

In this episode of Denatured, BioSpace’s Head of Insights Lori Ellis talks to Dr. Peter Marks, Director, CBER about his thoughts on the future of cell and gene therapies.

January 16, 2025

1 min read

Lori Ellis

FDA signage at its headquarters in Maryland

Regulatory

After Letter to Commissioner, FDA Finally Gives Vanda Reason for Rejection, Chance for Hearing

After a series of strongly worded letters—one of which was addressed directly to Commissioner Robert Califf—the FDA has publicly laid out its reasoning for rejecting Vanda Pharmaceuticals’ gastroparesis drug candidate tradipitant.

January 16, 2025

2 min read

Tristan Manalac

San Francisco, USA - May 20, 2022: historic Cable Car Powell Hyde Line on turntable at Powell Street terminal at Market Street in downtown San Francisco, California CA, USA.

Pipeline

JPM25 Day 3: AbbVie, Gilead, GSK and Dyne

AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for sustainable success in 2025.

January 16, 2025

3 min read

Tristan Manalac

Eli Lilly's biotechnology center in California

Immunology and inflammation

Lilly’s I&I Push Gains Momentum With Omvoh Expansion

Omvoh’s label expansion is important progress for Eli Lilly as it works to diversify its portfolio beyond obesity, according to analysts from BMO Capital Markets.

January 16, 2025

2 min read

Tristan Manalac

Businesswoman manager raised pointing growth direction on arrow. business and investment concept. vector illustration eps

Pipeline

BioNTech Strives to Become Commercial ‘Powerhouse’ While Maintaining Humility

Annemarie Hanekamp has overseen some of the most transformative changes in oncology over her years in Big Pharma. Now, she will oversee BioNTech’s transition from a COVID-19 vaccine maker to an “end-to-end organizational oncology powerhouse.”

January 16, 2025

4 min read

Annalee Armstrong

Art collage, hands and scales of justice. The concept of the law of the judge.

Legal

HHS Says Vertex is ‘Grasping at Straws’ With Casgevy Fertility Suit

Along with its gene editing therapy Casgevy, Vertex is offering fertility preservation support for its patients—a program that the HHS claims violates anti-kickback statutes.

January 16, 2025

2 min read

Tristan Manalac

Women holding hands over a red circle on a geometric shapes background

Business

Under Pressure to Deal, Biogen Executives Deflect Urgency at JPM25

While investors and analysts push for a deal, Biogen CEO Chris Viehbacher and Head of Development Priya Singhal refuse to make one out of desperation.

January 15, 2025

3 min read

Annalee Armstrong